Bridgeway Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Bridgeway Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-77,000	Closed	-$64.1K	–	1273
2026 Q1	$64.1K	Hold	77,000	–	–	﹤0.01%	1171
2025 Q4	$48.8K	Sell	77,000 -25,000	-25%	-$30.4K	﹤0.01%	1184
2025 Q3	$201K	Hold	102,000	–	–	﹤0.01%	1008
2025 Q2	$111K	Buy	102,000 +62,414	+158%	+$64.2K	﹤0.01%	1053
2025 Q1	$38.5K	Sell	39,586 -70,000	-64%	-$91.7K	﹤0.01%	1133
2024 Q4	$162K	Buy	109,586 +21,500	+24%	+$43.8K	﹤0.01%	1041
2024 Q3	$187K	Sell	88,086 -37,000	-30%	-$84.2K	﹤0.01%	1082
2024 Q2	$305K	Buy	125,086 +40,000	+47%	+$192K	0.01%	969
2024 Q1	$551K	Hold	85,086	–	–	0.01%	898
2023 Q4	$328K	Sell	85,086 -10,425	-11%	-$26.6K	0.01%	1051
2023 Q3	$204K	Buy	95,511 +10,000	+12%	+$27.6K	0.01%	1097
2023 Q2	$261K	Buy	85,511 +3,800	+5%	+$10.7K	0.01%	1073
2023 Q1	$212K	Hold	81,711	–	–	0.01%	1094
2022 Q4	$168K	Buy	81,711 +40,000	+96%	+$105K	﹤0.01%	1130
2022 Q3	$188K	Buy	41,711 +5,500	+15%	+$29.9K	0.01%	1153
2022 Q2	$148K	Buy	+36,211	New	+$165K	﹤0.01%	1153

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bridgeway Capital Management's HOWL Position: Q2 2026 in Review

Bridgeway Capital Management sold out of Werewolf Therapeutics (HOWL) in Q2 2026, closing a stake of 77,000 shares — an estimated $64.1K sold.

Bridgeway Capital Management first reported a position in HOWL in Q2 2022 and held it in 16 quarters. The position peaked at $551K in Q1 2024. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

Bridgeway Capital Management reported no remaining Werewolf Therapeutics position as of Q2 2026 after selling out during the quarter.
Bridgeway Capital Management sold 77,000 Werewolf Therapeutics shares in Q2 2026, an estimated $64.1K.
Bridgeway Capital Management first reported a position in Werewolf Therapeutics in Q2 2022 and held it in 16 quarters.
Bridgeway Capital Management's Werewolf Therapeutics position peaked at $551K in Q1 2024.
45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.